Long-term complete response in a patient with postoperative recurrent ALK-rearranged lung adenocarcinoma treated with crizotinib: A case report

被引：5

作者：

Kosaka, Takayuki ^{[1
]}

Yajima, Toshiki ^{[1
]}

Yamaki, Ei ^{[1
]}

Nakazawa, Seshiru ^{[1
]}

Tomizawa, Kenji ^{[1
]}

Onozato, Ryoichi ^{[1
]}

Yamazaki, Ayako ^{[2
]}

Hirato, Junko ^{[2
]}

Yatabe, Yasushi ^{[3
]}

Shimizu, Kimihiro ^{[1
]}

Mogi, Akira ^{[1
]}

Shirabe, Ken ^{[1
]}

机构：

[1] Gunma Univ, Dept Gen Surg Sci, Grad Sch Med, 3-39-22 Showa Machi, Maebashi, Gunma 3718511, Japan

[2] Gunma Univ Hosp, Dept Pathol, Maebashi, Gunma 3718511, Japan

[3] Aichi Canc Ctr, Dept Pathol & Mol Diagnost, Nagoya, Aichi 4648681, Japan

来源：

MOLECULAR AND CLINICAL ONCOLOGY | 2019年 / 11卷 / 03期

关键词：

crizotinib; anaplastic lymphoma kinase; non-small cell lung cancer; lung adenocarcinoma; post-operative recurrence; FUSION VARIANTS; OPEN-LABEL; CHEMOTHERAPY; CANCER;

D O I：

10.3892/mco.2019.1892

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Anaplastic lymphoma kinase (ALK) gene rearrangements are identified in approximately 5% of patients with non-small cell lung cancer (NSCLC). Despite initial dramatic responses to ALK inhibitors, the majority of patients relapse within 1 year, owing to the development of resistance. Herein we present a case of variant type 2 ALK-rearranged lung adenocarcinoma recurrence with multiple lung metastasis that maintained complete response over 5 years with crizotinib, which is the first approved ALK inhibitor. The efficacy of crizotinib may vary among ALK fusion variants and thus, variant type may represent an important factor in guiding the treatment strategy for ALK-rearranged lung adenocarcinoma.

引用

页码：309 / 312

页数：4

共 20 条

[1] Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants [J].

Cha, Yoon Jin ;

Kim, Hye Ryun ;

Shim, Hyo Sup .

JOURNAL OF TRANSLATIONAL MEDICINE, 2016, 14

[2] Differential Protein Stability and ALK Inhibitor Sensitivity of EML4-ALK Fusion Variants [J].

Heuckmann, Johannes M. ;

Balke-Want, Hyatt ;

Malchers, Florian ;

Peifer, Martin ;

Sos, Martin L. ;

Koker, Mirjam ;

Meder, Lydia ;

Lovly, Christine M. ;

Heukamp, Lukas C. ;

Pao, William ;

Kueppers, Ralf ;

Thomas, Roman K. .

CLINICAL CANCER RESEARCH, 2012, 18 (17) :4682-4690

[3] EML4-ALK: Honing In on a New Target in Non-Small-Cell Lung Cancer [J].

Horn, Leora ;

Pao, William .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (26) :4232-4235

[4] Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial [J].

Kim, Dong-Wan ;

Tiseo, Marcello ;

Ahn, Myung-Ju ;

Reckamp, Karen L. ;

Hansen, Karin Holmskov ;

Kim, Sang-We ;

Huber, Rudolf M. ;

West, Howard L. ;

Groen, Harry J. M. ;

Hochmair, Maximilian J. ;

Leighl, Natasha B. ;

Gettinger, Scott N. ;

Langer, Corey J. ;

Rodriguez, Luis G. Paz-Ares ;

Smit, Egbert F. ;

Kim, Edward S. ;

Reichmann, William ;

Haluska, Frank G. ;

Kerstein, David ;

Camidge, D. Ross .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (22) :2490-+

[5] Anaplastic Lymphoma Kinase Variants and the Percentage of ALK-Positive Tumor Cells and the Efficacy of Crizotinib in Advanced NSCLC [J].

Lei, Yuan-Yuan ;

Yang, Jin-Ji ;

Zhang, Xu-Chao ;

Zhong, Wen-Zhao ;

Zhou, Qing ;

Tu, Hai-Yan ;

Tian, Hong-Xia ;

Guo, Wei-Bang ;

Yang, Lu-Lu ;

Yan, Hong-Hong ;

Chen, Hua-Jun ;

Xie, Zhi ;

Su, Jian ;

Han, Jie-Fei ;

Wu, Yi-Long .

CLINICAL LUNG CANCER, 2016, 17 (03) :223-231

[6] Large-Scale Screening and Molecular Characterization of EML4-ALK Fusion Variants in Archival Non-Small-Cell Lung Cancer Tumor Specimens Using Quantitative Reverse Transcription Polymerase Chain Reaction Assays [J].

Li, Tianhong ;

Maus, Martin K. H. ;

Desai, Sonal J. ;

Beckett, Laurel A. ;

Stephens, Craig ;

Huang, Eric ;

Hsiang, Jack ;

Zeger, Gary ;

Danenberg, Kathleen D. ;

Astrow, Stephanie H. ;

Gandara, David R. .

JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (01) :18-25

[7] Response to crizotinib in advanced &ITALK&IT-rearranged non-small cell lung cancers with different &ITALK&IT-fusion variants [J].

Li, Yan ;

Zhang, Tongtong ;

Zhang, Jing ;

Li, Wenbin ;

Yuan, Pei ;

Xing, Puyuan ;

Zhang, Zhou ;

Chuai, Shannon ;

Li, Junling ;

Ying, Jianming .

LUNG CANCER, 2018, 118 :128-133

[8] Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer [J].

Lin, Jessica J. ;

Zhu, Viola W. ;

Yoda, Satoshi ;

Yeap, Beow Y. ;

Schrock, Alexa B. ;

Dagogo-Jack, Ibiayi ;

Jessop, Nicholas A. ;

Jiang, Ginger Y. ;

Le, Long P. ;

Gowen, Kyle ;

Stephens, Philip J. ;

Ross, Jeffrey S. ;

Ali, Siraj M. ;

Miller, Vincent A. ;

Johnson, Melissa L. ;

Lovly, Christine M. ;

Hata, Aaron N. ;

Gainor, Justin F. ;

Iafrate, Anthony J. ;

Shaw, Alice T. ;

Ou, Sai-Hong Ignatius .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (12) :1199-+

[9] Five-Year Survival in EGFR-Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs [J].

Lin, Jessica J. ;

Cardarella, Stephanie ;

Lydon, Christine A. ;

Dahlberg, Suzanne E. ;

Jackman, David M. ;

Jaenne, Pasi A. ;

Johnson, Bruce E. .

JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) :556-565

[10] ALK fusion variants detection by targeted RNA-next generation sequencing and clinical responses to crizotinib in ALK-positive non-small cell lung cancer [J].

McLeer-Florin, Anne ;

Duruisseaux, Michael ;

Pinsolle, Julian ;

Dubourd, Sylvian ;

Mondet, Julie ;

Houlbracq, Mathilde Phillips ;

Magnat, Nelly ;

Faure, Julien ;

Chatagnon, Amandine ;

de Fraipont, Florence ;

Levra, Matteo Giaj ;

Toffart, Anne-Claire ;

Ferretti, Gilbert ;

Hainaut, Pierre ;

Brarribilla, Elisabeth ;

Moro-Sibilot, Denis ;

Lantuejoul, Sylvie .

LUNG CANCER, 2018, 116 :15-24

← 1 2 →